Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

The FDA has granted approval to adjuvant cemiplimab treatment for patients with high-risk cutaneous squamous cell carcinoma after surgery and radiation. The FDA has approved the adjuvant use of ...

HR+/HER2- breast cancer is the most common subtype of the disease, representing approximately 70% of all breast cancer cases.

Oncology nurse practitioners discuss CD38-based frontline therapy for newly diagnosed multiple myeloma, including Dara-VRd ...

FDA approves once-daily ruxolitinib XR for MF, PV and GVHD, offering simplified dosing with comparable drug exposure to twice ...

The standard mandates the use of Closed System Transfer Devices (CSTDs) for drug administration—a move Olsen calls a “big win ...

This Rx Road Map outlines the most important information nurses should know when treating patients with astrocytoma or oligodendroglioma with vorasidenib. This was the FDA’s first approval of a ...

Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared ...

FDA expands Alpha DaRT IMPACT trial to 40 patients, adding gemcitabine and nab-paclitaxel cohort in pancreatic cancer.

The selective internal radiation therapy SIR-Spheres has been approved by the FDA for use in patients with unresectable hepatocellular carcinoma. The FDA has approved SIR-Spheres Y-90 resin ...

Dr. Azmi emphasized that oncology nurses are often on the front lines of patient education and can play a critical role in ...

FDA accepts Zanidatamab combo sBLA for HER2+ gastroesophageal cancer, showing improved outcomes in HERIZON-GEA-01 trial with ...